Ampio Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 6.41 million compared to USD 3.63 million a year ago. Basic loss per share from continuing operations was USD 8.6 compared to USD 5.4 a year ago. Diluted loss per share from continuing operations was USD 10 compared to USD 5.8 a year ago.
For the nine months, net loss was USD 14.12 million compared to USD 10.85 million a year ago. Basic loss per share from continuing operations was USD 18.8 compared to USD 16.4 a year ago. Diluted loss per share from continuing operations was USD 25.8 compared to USD 17.2 a year ago.